Hibernator “superpowers” may lie hidden in human DNA
July 31, 2025 / Hibernation genetics / Human metabolism / Type 2 diabetes research / Neurodegeneration therapy / Obesity gene FTO
Genetic studies of hibernating animals reveal human DNA may hold similar metabolic “switches,” potentially enabling therapies to reverse type 2 diabetes, neurodegeneration, and obesity by mimicking hibernators’ ability to regulate metabolism, protect muscles, and recover from extreme physiological stress.
The metabolic advantage of being young and male in obesity treatment outcomes in mice
August 1, 2025 / Obesity treatment / Bariatric surgery outcomes / Age and sex metabolism / White adipose tissue / Intermittent fasting benefits
In obese mice, younger age and male sex enhanced weight loss after bariatric surgery or intermittent fasting, linked to greater white adipose tissue (WAT) mobilization and transcriptomic flexibility, while aging and female sex hindered metabolic improvements and fat reduction.
Metabolic Health in Schizophrenia: Toward Nutritional and Metabolism-Based Strategies in Psychiatry
August 4, 2025 / Schizophrenia metabolism / Antipsychotic weight gain / Metabolic syndrome risk / Nutritional psychiatry / Type 2 diabetes prevention
Schizophrenia patients face high metabolic syndrome risk due to antipsychotic-induced weight gain, poor diet, and insulin resistance. Conventional lifestyle interventions show limited efficacy, highlighting the need for targeted metabolic and nutritional strategies to prevent obesity and type 2 diabetes.
Mechanisms of metabolic surgery effectiveness in obesity and type 2 diabetes: a puzzle with some known pieces
July 31, 2025 / Metabolic surgery / Type 2 diabetes treatment / GI-brain axis / Obesity pharmacotherapy / Vagal nerve signaling
Metabolic surgery improves obesity and type 2 diabetes by altering the GI-brain vagal axis to regulate appetite and metabolism. Understanding these neural mechanisms may enable development of noninvasive pharmacologic therapies targeting NMDA or GABA receptors to mimic surgical benefits.
Obesity and Diabetes May Be Treated with Gut Bacteria Peptides
August 1, 2024 / Gut microbiome therapy / Obesity treatment / Diabetes management / Bacterial peptides / Pharmabiotics research
University of Copenhagen researchers identified gut bacterial peptides, RORDEP1 and RORDEP2, that regulate blood sugar, reduce weight gain, and enhance bone density in animal models, offering a potential foundation for future pharmabiotic therapies for obesity, diabetes, and metabolic diseases.
Eating meals earlier could help people at high obesity risk
July 30, 2025 / Meal timing obesity / Genetic obesity risk / Weight loss maintenance / Circadian metabolism / Early eating benefits
A Spanish study found that earlier meal timing improves long-term weight maintenance in overweight adults, especially those with high genetic obesity risk, while each hour of delayed eating increases BMI and weight regain despite similar calorie intake during treatment.
Painless saliva insulin test offers early signs of diabetes and obesity risk
UBC researchers developed a painless saliva test to measure insulin, enabling early detection of hyperinsulinemia—a precursor to obesity, type 2 diabetes, and cardiovascular disease—years before standard blood tests reveal metabolic dysfunction, supporting proactive lifestyle and clinical interventions.
Saliva testing may reveal early signs of diabetes and obesity
July 31, 2025 / Saliva insulin test / Early diabetes detection / Obesity risk screening / Hyperinsulinemia biomarker / Noninvasive metabolic testing
UBC researchers found saliva insulin testing can detect hyperinsulinemia, an early marker for type 2 diabetes, obesity, and cardiovascular risk, even in lean individuals with normal blood sugar, offering a simple, non-invasive tool for early metabolic risk identification.
Dynapenic Obesity Contributes to Cardiometabolic Disease Progression
UK Biobank data show dynapenic obesity—low handgrip strength with general or abdominal obesity—significantly increases risk of cardiometabolic disease, multimorbidity, and death, partly mediated by inflammation (CRP) and atherogenic lipid profiles (AIP), emphasizing muscle strength’s role in metabolic health.
Eli Lilly’s Mounjaro Outperforms Trulicity in Cardiovascular and Metabolic Outcomes—A Game Changer for Diabetes and Obesity Markets?
July 31, 2024 / Tirzepatide Mounjaro / Dual GLP-1 GIP agonist / Cardiometabolic risk reduction / Type 2 diabetes therapy / Obesity weight loss
Eli Lilly’s tirzepatide (Mounjaro/Zepbound) outperformed Trulicity in reducing cardiovascular events, mortality, and weight while improving glycemic and renal outcomes, positioning this dual GLP-1/GIP agonist as a transformative therapy for type 2 diabetes, obesity, and cardiometabolic risk reduction.
Muscle Strength Tied to Metabolic Risk in Paediatric Obesity
July 30, 2025 / Pediatric obesity / Muscle strength metabolism / Metabolic syndrome risk / Standing broad jump / Childhood cardiometabolic health
In children with obesity, lower muscle strength—measured by standing broad jump—was strongly linked to higher metabolic syndrome risk, elevated BMI, and increased blood pressure, highlighting the importance of muscular fitness in pediatric cardiometabolic health.
Gut microbial metabolites restore hormone-producing cells in obesity
July 29, 2025 / Gut microbiome therapy / Enteroendocrine cells / Obesity metabolic health / Tryptophan metabolites / GLP-1 hormone restoration
Marshall University researchers found that gut microbial metabolites, particularly indole from dietary tryptophan, can restore hormone-producing enteroendocrine cells in obesity, potentially improving GLP-1 secretion, insulin sensitivity, and metabolic health, supporting microbiota-targeted therapies for obesity management.
Study finds animal-based fats fuel tumor growth in obese mice, plant fats do not
July 30, 2025 / Obesity cancer risk / Animal vs plant fats / Tumor immune suppression / NK and T-cell function / Dietary fat and cancer
A Nature Metabolism study found that animal-based fats accelerate tumor growth in obese mice by suppressing NK and cytotoxic T-cell function, whereas plant-based fats do not, suggesting dietary fat source influences obesity-related cancer risk and treatment outcomes.
The vicious circle of aging and metabolic dysfunction-associated steatotic liver disease
August 1, 2025 / MASLD liver aging / Hepatic senescence / Steatosis and fibrosis / Senolytic therapy / Metabolic liver disease
Aging and MASLD reinforce each other through liver cell senescence, driving steatosis, inflammation, and fibrosis. Targeting senescent hepatocytes, stellate cells, and Kupffer macrophages with senolytics or lifestyle interventions shows promise for reversing metabolic dysfunction and preventing progressive liver disease.
CagriSema Promotes Rat Weight Loss by Balancing Energy
August 3, 2025 / CagriSema peptide / Obesity therapy / Energy balance metabolism / Weight loss mechanism / Metabolic disorder treatment
CagriSema, a dual-acting peptide, induces weight loss in obese rats by reducing caloric intake while preserving energy expenditure, avoiding the typical metabolic slowdown and offering a promising approach for future obesity and metabolic disorder therapies.
Chulalongkorn Bariatric and Metabolic Institute (Chula BMI), a One-Stop Service Center for Holistic Obesity Treatment
August 1, 2025 / ‘Holistic obesity treatment / Bariatric surgery center / Multidisciplinary weight management / Metabolic disease care / Chula BMI Thailand
Chula BMI provides multidisciplinary, one-stop obesity care, integrating lifestyle interventions, medications, and bariatric surgery. Tailored treatment aims to improve metabolic health, manage obesity-related comorbidities, and support long-term weight maintenance through coordinated medical, nutritional, behavioral, and surgical strategies.
Targeting Liver Cancer Metabolism Helps Immune System Destroy Tumors
August 1, 2025 / Liver cancer metabolism / ACLY inhibition therapy / B cell tumor immunity / Fatty liver disease risk / Hepatocellular carcinoma treatment
McMaster researchers developed EVT0185, an ACLY inhibitor that disrupts liver cancer fat metabolism, enhancing B cell–mediated immune responses and reducing tumors in MASH-associated liver cancer models, offering a potential new therapy for fatty liver–related hepatocellular carcinoma.
Radella Pharmaceuticals Announces New Obesity Trial Data Showing Statistically Significant Weight Loss and Broader Cardiometabolic Benefits
July 31, 2025 / Obesity clinical trial / Leptin signaling therapy / PTP1B inhibition / Cardiometabolic health benefits / MD-18 weight loss
Radella’s MD-18, a first-in-class peptide targeting PTP1B to restore leptin signaling, achieved significant weight loss and cardiometabolic improvements in a Phase 1b trial, increasing insulin sensitivity and energy expenditure while preserving lean mass with favorable safety.
Noom’s Strategic Move into Compounded GLP-1s: A Disruptive Play in the Weight-Loss Market
August 4, 2025 / Compounded GLP-1 therapy / Digital obesity management / Noom weight loss / Microdosing GLP-1s / Behavioral health integration
Noom integrates compounded GLP-1 therapy with behavioral coaching in a digital health platform, leveraging microdosing to reduce side effects and costs, aiming to improve long-term obesity management and expand access amid regulatory and market challenges.
Could These Food Products Act as a Natural Ozempic?
August 4, 2025 / Tryptophan metabolites / Gut microbiome obesity / GLP-1 hormone production / Enteroendocrine cell restoration / Natural Ozempic alternative
Research shows that gut microbial metabolites from dietary tryptophan can restore GLP-1–producing enteroendocrine cells lost in obesity, potentially improving insulin sensitivity, appetite control, and metabolic health as a natural alternative to drugs like Ozempic.